Therapeutic landscape of metaplastic breast cancer
| Autor: | J. Taff, Nancy Tray, S. Adams |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
0301 basic medicine
Epithelial-Mesenchymal Transition medicine.drug_class Breast Neoplasms Unmet needs 03 medical and health sciences 0302 clinical medicine Breast cancer Immune system medicine Biomarkers Tumor PTEN Animals Humans Radiology Nuclear Medicine and imaging Triple negative Neoplasm Staging Clinical Trials as Topic biology Genetic heterogeneity business.industry Disease Management Genetic Variation General Medicine medicine.disease Combined Modality Therapy Clinical trial 030104 developmental biology Treatment Outcome Oncology Estrogen 030220 oncology & carcinogenesis biology.protein Cancer research Neoplastic Stem Cells Female business |
| Zdroj: | Cancer treatment reviews. 79 |
| ISSN: | 1532-1967 |
| Popis: | Metaplastic breast carcinomas (MPBC) are rare, aggressive and relatively chemorefractory tumors with a high unmet need. While most are "triple negative" and lack expression of estrogen, progesterone and HER2 receptors, MPBC are associated with worse outcomes compared to conventional triple negative invasive tumors. MPBCs are genetically heterogeneous and harbor somatic mutations, most frequently in TP53, PIK3CA and PTEN, with emerging studies suggesting a role for novel targeted therapies. These tumors have also been associated with overexpression of PD-L1 and tumor-infiltrating lymphocytes suggesting an endogenous immune response and therefore a rationale for treatment with immunotherapies. Here, we focus on therapeutic options for this difficult to treat breast cancer subtype and encourage physicians to consider targeted therapies/immunotherapies as part of ongoing clinical trials. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect